Cerenis Therapeutics Featured Prominently at the 25th Conference of the ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER (APASL)

Experimental results demonstrate an active role to treat atherosclerosis and non-alcoholic steatohepatitis (NASH) for CER-209 as an agonist of the P2Y13 receptor

TOULOUSE, France & ANN ARBOR, Mich.--()--Cerenis Therapeutics (FR0012616852- CEREN) (Paris:CEREN), an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies (“good cholesterol”) for treating cardiovascular and metabolic diseases, today reported two poster presentations featuring Cerenis Therapeutics’ innovative HDL therapy, CER-209, during the 25th Conference of the APASL held in Tokyo, February 20-24, 2016.

  • CER-209, an agonist of the P2Y13 receptor, is potentially well suited to the treatment of atherosclerosis and non-alcoholic steatohepatitis (NASH)

In a poster presentation (“P2Y13 receptor agonist CER-209 decreases both atherosclerosis and liver steatosis in vivo”), Cerenis presented results of CER-209, a selective novel agonist of the P2Y13 receptor (P2Y13R) that caused an increased uptake of high-density lipoprotein-cholesterol (HDL-c) in the liver which is associated with stimulation of bile acid secretion. Repeated dose administration of CER-209 stimulated the apoA-I synthesis and formation of small HDL particles, known to be atheroprotective. CER-209-treated plasma samples had high cholesterol efflux capacity for the mobilization of cellular cholesterol in vitro compared with the placebo group. CER-209 induced a decrease in atherosclerotic plaques in aorta and carotids as well as a remarkable decrease in the steatosis in a validated preclinical model.

To read the complete press release, please visit Cerenis’ corporate website

About Cerenis Therapeutics: www.cerenis.com

Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body.

Cerenis is developing a portfolio of HDL therapies, including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as post-ACS patients and patients with HDL deficiency, and drugs which increase HDL for patients with low number of HDL particles to treat atherosclerosis and associated metabolic diseases.

Cerenis is well-positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs being developed.

Since its inception in 2005, the company has been funded by top tier investors: Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/IXO Private Equity and Bpifrance (Fund for Strategic Investment) and last March successfully completed an IPO on Euronext raising €53.4m.

About CER-209:

CER-209 is the first drug candidate in the category of oral P2Y13 receptor agonists. The P2Y13 receptor is a member of the P2Y receptor family, a well-known receptor family including the P2Y12 receptor which is the target of successful drugs such as the anti-thrombotic agent Clopidogrel (Plavix®). In preclinical studies CER-209 promotes HDL recognition by the liver and increase the activity of Reverse Lipid Transport (RLT), and thus has an impact on atherosclerosis regression. Because of the favorable metabolic effects observed in the liver, CER-209 may also offer a new mechanism for the treatment of non-alcoholic steato-hepatitis (NASH).

About CER-001:

CER-001 is an engineered complex of recombinant human apoA-I, the major structural protein of HDL, and phospholipids. It has been designed to mimic the structure and function of natural, nascent HDL, also known as pre-beta HDL. Its mechanism of action is to increase apoA-I and the number of HDL particles transiently, to stimulate the removal of excess cholesterol and other lipids from tissues including the arterial wall and to transport them to the liver for elimination through a process called Reverse Lipid Transport. Previous Phase II studies have provided important data demonstrating the efficacy of CER-001 in regressing atherosclerosis in several distinct vascular beds in patients representing the entire spectrum of cholesterol homeostasis. The totality of the data to date indicates that CER-001 performs all of the functions of natural pre-beta HDL particles and has the potential to be the best-in-class HDL mimetic in the market.

Contacts

Cerenis
Jean-Louis Dasseux, Tel: +33 (0)5 62 24 09 49
CEO
info@cerenis.com
or
NewCap
Investors relations
Emmanuel Huynh / Louis-Victor Delouvrier
cerenis@newcap.eu
Tel: +33 (0)1 44 71 98 53
or
NewCap
Media relations
Nicolas Merigeau, Tel: +33 (0)1 44 71 94 98
cerenis@newcap.eu

Contacts

Cerenis
Jean-Louis Dasseux, Tel: +33 (0)5 62 24 09 49
CEO
info@cerenis.com
or
NewCap
Investors relations
Emmanuel Huynh / Louis-Victor Delouvrier
cerenis@newcap.eu
Tel: +33 (0)1 44 71 98 53
or
NewCap
Media relations
Nicolas Merigeau, Tel: +33 (0)1 44 71 94 98
cerenis@newcap.eu